Colacci M, Raissi A, Ray P, Sholzberg M, Rothman KJ, Fralick M. Randomized controlled trials of switching to a new medication vs continuing a chronic medication may underestimate the risk of adverse events in those continuing because of asymmetric depletion of susceptibles. J Clin Epidemiol. 2024 Jun;170:111336. doi: 10.1016/j.jclinepi.2024.111336
Ali MS, Berencsi K, Marinier K, Deltour N, Perez-Gutthann S, Pedersen L, Rijnbeek P, Lapi F, Simonetti M, Reyes C, Van der Lei J, Sturkenboom M, Prieto-Alhambra D. Comparative cardiovascular safety of strontium ranelate and bisphosphonates: a multi-database study in 5 EU countries by the EU-ADR Alliance. Osteoporos Int. 2020 Dec;31(12):2425-38.
Gilsenan A, Harris D, Reynolds M, McSorley D, Midkiff K, Jackson L, Muldavin B, Kellier-Steele N, Andrews E. Long-term cancer surveillance: results from the Forteo Patient Registry Surveillance Study. Osteoporos Int. 2020 Nov 5;32(4):645-51. doi: 10.1007/s00198-020-05718-0
Berencsi K, Sami A, Ali MS, Marinier K, Deltour N, Perez-Gutthann S, Pedersen L, Rijnbeek P, Van der Lei J, Lapi F, Simonetti M, Reyes C, Sturkenboom MCJM, Prieto-Alhambra D. Impact of risk minimisation measures on the use of strontium ranelate in Europe: a multi-national cohort study in 5 EU countries by the EU-ADR Alliance. Osteoporos Int. 2020 Apr;31(4):721-55. doi: 10.1007/s00198-020-05314-2
Pajouheshnia R, van Smeden M, Peelen LM, Groenwold RHH. How variation in predictor measurement affects the discriminative ability and transportability of a prediction model. J Clin Epidemiol. 2019 Jan;105:136-41. doi: 10.1016/j.jclinepi.2018.09.001
Gilsenan A, Harding A, Kellier-Steele N, Harris D, Midkiff K, Andrews E. The Forteo patient registry linkage to multiple state cancer registries: study design and results from the first 8 years. Osteoporos Int. 2018 Oct;29(10):2335-43. doi: 10.1007/s00198-018-4604-8
Groenwold RHH, Moons KGM, Pajouheshnia R, Altman DG, Collins GS, Debray TPA, Reitsma JB, Riley RD, Peelen LM. Explicit inclusion of treatment in prognostic modeling was recommended in observational and randomized settings. J Clin Epidemiol. 2016 Oct;78:90-100. doi: 10.1016/j.jclinepi.2016.03.017
Hoffman V, Xue F, Gardstein B, Skerry K, Critchlow CW, Enger C. Assessment of off-label use of denosumab 60 mg injection during the early postmarketing period using health insurance claims data. Osteoporos Int. 2016 Apr;27(4):1653-8. doi: 10.1007/s00198-015-3402-9
Boccia S, Rothman KJ, Panic N, Flacco ME, Rosso A, Pastorino R, Manzoli L, La Vecchia C, Villari P, Boffetta P, Ricciardi W, Ioannidis JP. Registration practices for observational studies on ClinicalTrials.gov indicated low adherence. J Clin Epidemiol. 2016 Feb;70:176-82. doi: 10.1016/j.jclinepi.2015.09.009
Andrews EB, Gilsenan AW, Midkiff KD, Harris DH. Comments on Bang et al.: the impact of recombinant parathyroid hormone on malignancies and mortality: 7 years of experience based on nationwide Danish registers. Osteoporos Int. 2015 May;26(5):1663-4. doi: 10.1007/s00198-014-3003-z
Overman RA, Gourlay ML, Deal CL, Farley JF, Brookhart MA, Layton JB. Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis. Osteoporos Int. 2015 May;26(5):1515-24. doi: 10.1007/s00198-014-3022-9
McKenna SP, Twiss J, Crawford SR, Oprandi NC, Tammaru M, Miravitlles M. The living with chronic obstructive pulmonary disease scale was successfully adapted for use in southern european (Italian and Spanish) and eastern european (Russian) cultures. J Clin Epidemiol. 2012 Aug;65(8):906-14.
Herring WL, Herrmann JW. The single-day surgery scheduling problem: sequential decision-making and threshold-based heuristics. OR spectrum: quantitative approaches in management. 2012 Apr 1;34(2):429-59.
McLellan AR, Wolowacz SE, Zimovetz EA, Beard SM, Lock S, McCrink L, Adekunle F, Roberts D. Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int. 2011 Jul 1;22(7):2083-98.
Tosteson AN, Do TP, Wade SW, Anthony MS, Downs RW. Persistence and switching patterns among women with varied osteoporosis medication histories: 12-month results from POSSIBLE US. Osteoporos Int. 2010 Oct;21(10):1769-80. doi: 10.1007/s00198-009-1133-5
Gutierrez L, Roskell N, Rycroft C, Castellsague J, Beard S, Abeysinghe S, Shannon P, Robbins S, Gitlin M. Economic and clinical burden of non-vertebral non-hip (Nvnh), vertebral and multiple fractures in postmenopausal women in the United Kingdom. Poster presented at IOF World Congress on Osteoporosis & 10th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis; May 2010. Florence, Italy. [abstract] Osteoporos Int. 2010 May 1; 21(Suppl. 1):S96.
Castellsague J, Roskell N, Gutierrez L, Beard S, Rycroft C, Abeysinghe S, Shannon P, Robbins S, Gitlin M. Economic and clinical burden of hip fractures in postmenopausal women in the United Kingdom (UK). Poster presented at the IOF World Congress on Osteoporosis & 10th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis; May 2010. Florence, Italy. [abstract] Osteoporos Int. 2010 May 1; 21(Suppl. 1):S95.
Barrett-Connor E, Ensrud K, Tosteson AN, Varon SF, Anthony M, Daizadeh N, Wade S. Design of the POSSIBLE US trade mark study: postmenopausal women's compliance and persistence with osteoporosis medications. Osteoporos Int. 2009 Mar;20(3):463-72. doi: 10.1007/s00198-008-0674-3
Stuermer T, Rothman KJ, Avorn J. Pharmacoepidemiology and "in silico" drug evaluation: is there common ground? J Clin Epidemiol. 2008 Mar 1;61(3):205-6.
Drummond FJ, Sharp L, Carsin AE, Kelleher T, Comber H. Questionnaire order significantly increased response to a postal survey sent to primary care physicians. J Clin Epidemiol. 2008 Feb;61(2):177-85. doi: 10.1016/j.jclinepi.2007.04.012
Sturmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol. 2006 May 1;59(5):437-47.
Carnethon MR, Anthony MS, Cascio WE, Folsom AR, Rautaharju PM, Liao D, Evans GW, Heiss G. Prospective association between hormone replacement therapy, heart rate, and heart rate variability. The Atherosclerosis risk in communities study. J Clin Epidemiol. 2003 Jun;56(6):565-71.
Cella D, Eton DT, Faircloth DL, Bonomi P, Heyes AE, Silberman C, Wolf MK, Johnson DH. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy - Lung (FACT-L) questionnaire? Results from Eastern Cooperative Group (ECOG) Study 5592. J Clin Epidemiol. 2002 Mar;55(3):285-95.
Rothman KJ. My actual beliefs. J Clin Epidemiol. 2001 Dec 1;54(12):1275. doi: 10.1016/S0895-4356(01)00419-X
Clarkson TB, Cline JM, Williams JK, Anthony MS. Gonadal hormone substitutes: effects on the cardiovascular system. Osteoporos Int. 1997;7(Suppl 1):543-51.
Lanes SF, Rothman KJ. Tampon absorbency, composition and oxygen content and risk of toxic shock syndrome. J Clin Epidemiol. 1990 Jan 1;43(12):1379-85.
Poole C, Rothman KJ. Epidemiologic science and public health policy. J Clin Epidemiol. 1990 Jan 1;43(11):1270-1. doi: 10.1016/0895-4356(90)90029-O